Aiforia Technologies Plc, Company release, April 16, 2026 at 17:00 EEST
Aiforia Technologies Plc: Resolutions of the constitutive meeting of the Board of Directors
In its constitutive meeting held on 16 April 2026, the Board of Directors of Aiforia Technologies Plc elected Tuomas Tenkanen from among its members to serve as the Chair. Joseph Bernardo was elected Vice Chair of the Board.
Pursuant to the Board of Directors' assessment all members of the Board of Directors are independent of Aiforia and its significant shareholders, with the exception of Johan Lundin, who is assessed not to be independent of Aiforia and Jerry Jian Hong, who is assessed not to be independent of Aiforia's major shareholder Ascend Tapio S.a.r.l.
Composition of the Audit and Remuneration Committee
From among its members, the Board elected the following persons as members of the Board's Audit and Remuneration Committee: Tuomas Tenkanen (Chair), Joseph Bernardo and Minna Koivula.
Further inquiries:
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com